Showing all news

MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership in China to Develop Novel Therapeutics for Parkinson’s Disease

London, UK and Beijing, China, 21 November 2014: MRC Technology and Yabao Pharmaceutical Co, Inc., a leading pharmaceutical company in China, today announced an exclusive license agreement to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialise the therapeutics in China, Taiwan and Hong Kong whilst MRC Technology retains rights in all other markets. Financial terms have… Read More

21 November 2014

Catherine Kettleborough elected to SLAS Europe Council

Congratulations to Catherine Kettleborough, MRC Technology’s Associate Director of Drug Discovery Biology, who has been elected to the SLAS Europe Council for three years starting January 2015!

10 November 2014

Dr. John Stageman Appointed Chair of the Board for MRC Technology

London, UK, 29 September 2014: MRC Technology (MRCT), a UK medical research charity, today announced the appointment of Dr. John Stageman as Chair of its Board of Directors, and who takes over from John Jeans, the charity’s Chair for the last six years. Dr Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research. He has held a number of international R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. Latterly he led the team responsible for developing AstraZeneca’s competitive… Read More

29 September 2014

SciBX article about the Dementia Consortium

The 24 July issue of SciBX contains an article about the Dementia Consortium with a quote from our Director of Drug Discovery, Justin Bryans. The full article is available on the SciBX site.

24 July 2014

New paper published in EMBO Molecular Medicine

The inwardly rectifying K+ channel KIR7.1 controls uterine excitability throughout pregnancy McCloskey, C., Rada, C., Bailey, E., McCavera, S., van den Berg, H. A., Atia, J., Rand, D. A., Shmygol, A., Chan, Y.-W., Quenby, S., Brosens, J. J., Vatish, M., Zhang, J., Denton, J. S., Taggart, M. J., Kettleborough, C., Tickle, D., Jerman, J., Wright, P., Dale, T., Kanumilli, S., Trezise, D. J., Thornton, S., Brown, P., Catalano, R., Lin, N., England, S. K. and Blanks, A. M. (2014) EMBO Mol Med. doi: 10.15252/emmm.201403944  

24 July 2014
Showing all news